Shana Claeys

Years Active: 2018-2020
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Liselot M Mus, Irina Lambertz, Shana Claeys, Candy Kumps, Wouter Van Loocke, Christophe Van Neste, Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys, Olivier De Wever, Daniel Bexell, Matthias Fischer, Bengt Hallberg, Johannes Schulte, Bram De Wilde, Kaat Durinck, Geertrui Denecker, Katleen De Preter, Frank Speleman
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. Scientific reports 10 (1) (2020)
Shana Claeys, Geertrui Denecker, Kaat Durinck, Bieke Decaesteker, Liselot M Mus, Siebe Loontiens, Suzanne Vanhauwaert, Kristina Althoff, Caroline Wigerup, Daniel Bexell, Emmy Dolman, Kai-Oliver Henrich, Lea Wehrmann, Ellen M Westerhout, Jean-Baptiste Demoulin, Candy Kumps, Tom Van Maerken, Genevieve Laureys, Christophe Van Neste, Bram De Wilde, Olivier De Wever, Frank Westermann, Rogier Versteeg, Jan J Molenaar, Sven Påhlman, Johannes H Schulte, Katleen De Preter, Frank Speleman
ALK positively regulates MYCN activity through repression of HBP1 expression. Oncogene 38 (15) (2018)
Kristina Bennet Emdal, Anna-Kathrine Pedersen, Dorte B Bekker-Jensen, Alicia Lundby, Shana Claeys, Katleen De Preter, Frank Speleman, Chiara Francavilla, Jesper Velgaard Olsen
Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Science signaling 11 (557) (2018)

Shana Claeys.css-eqlu8i{font-size:small;padding-left:4px;}